about
Gastric inhibitory polypeptide receptor methylation in newly diagnosed, drug-naïve patients with type 2 diabetes: a case-control studyDifferential methylation of TCF7L2 promoter in peripheral blood DNA in newly diagnosed, drug-naïve patients with type 2 diabetesREV-ERB ALPHA polymorphism is associated with obesity in the Spanish obese male populationEffects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial.Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes.Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetesDiagnosis and classification of autoimmune diabetes mellitus.Hypertension remission 1 year after bariatric surgery: predictive factors.Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention.[The evolution of quality care indicators of patients with type 2 diabetes in the Spanish primary care (1996-2007). The RedGEDAPS quality of care program].Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study.Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress.Haptoglobin genotype and risk of diabetic nephropathy in patients with type 1 diabetes mellitus: a study on a Spanish population.Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.Circulating SFRP5 levels are elevated in drug-naïve recently diagnosed type 2 diabetic patients as compared with prediabetic subjects and controlsSimultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 DiabetesLos problemas de salud también explican la utilización de servicios sociales en atención domiciliaria[Is the control of cardiovascular risk factors in secondary prevention adequate?][Drug related problems and hospital admissions]Glucose abnormalities associated with impaired nocturnal fall in blood pressure in normotensive severely obese patientsmiR-10b and miR-223-3p in serum microvesicles signal progression from prediabetes to type 2 diabetesGlycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting
P50
Q28533735-CF1EC4D2-3996-4B13-8E66-3453813A6382Q28539538-57EAC2FD-B806-4B25-80A6-4B8516E59D43Q33999999-7B93B783-7C31-4DC0-B6BC-3CB712E9A1D7Q36811058-6A94B232-3BF7-4C08-9A32-7211B1DC161FQ36976130-C9685363-3B89-4265-89FF-DB5E27022482Q37022682-E0D592AF-D58B-45B9-A5F3-9B0CCC0DB604Q37331242-03A20F90-61B3-44CF-BC22-467995D339F3Q38178468-F55A582D-37C1-46A0-995F-7083EE06E7E8Q38192271-E74D7840-32D1-47B8-BCF5-E4A589B63CE5Q41659225-F57BDB0A-B959-461D-B246-9B7772CFD2ECQ43274399-17F5F8D3-3C5E-4FCE-954F-8E96BB2F4F3BQ47319650-76468CA9-2F2B-4317-90E0-C40C76340BACQ50457112-D81ADB46-9F7D-456F-B4F2-CE9A1CC359A8Q54216687-DF05D50C-CB61-4B51-95BA-D0F7E8FDF3E2Q54940707-69768615-D986-40C3-8DE6-1810B53321ABQ58828952-E84C226D-FFEA-4412-97BA-D4750617BE62Q58828967-E1F67207-BD16-489F-9543-2502C19827DFQ59285671-5652C6C9-A718-42F1-9F37-E7D6565957AFQ83283971-38ACE2C0-CFAD-45E0-891F-48DD72AE4047Q83629821-911F4145-99C3-4F0A-B3AD-97107F72A9F8Q87001843-2B9269FB-3961-4E03-B407-B02686BE33FDQ91265294-5F24D5CA-942F-4007-AAFF-54D6DA9E18D3Q91526197-D7D2E25A-3DA8-46E4-921C-C29DE56FC1C1
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Canivell
@ast
Silvia Canivell
@en
Silvia Canivell
@es
Silvia Canivell
@nl
type
label
Silvia Canivell
@ast
Silvia Canivell
@en
Silvia Canivell
@es
Silvia Canivell
@nl
prefLabel
Silvia Canivell
@ast
Silvia Canivell
@en
Silvia Canivell
@es
Silvia Canivell
@nl
P106
P21
P31
P496
0000-0002-0280-5035